{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:02:23Z","timestamp":1773252143075,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:04:21Z","timestamp":1759997061000},"page":"e254-e260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF\u2019s CureCloud Initiative"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5023","authenticated-orcid":false,"given":"Mark A","family":"Fiala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5247-7745","authenticated-orcid":false,"given":"Eva","family":"Lepisto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chioma","family":"Amadi-Mgbenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.10.007_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics. CA: a","volume":"69","author":"Siegel","year":"2019","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.clml.2025.10.007_bib0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","article-title":"Limits on Medicare\u2019s ability to control rising spending on cancer drugs","volume":"360","author":"Bach","year":"2009","journal-title":"New Eng J Med."},{"issue":"24","key":"10.1016\/j.clml.2025.10.007_bib0003","first-page":"2757","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective blood","volume":"128","author":"Rajkumar","year":"2016","journal-title":"J Am Society Hematol"},{"key":"10.1016\/j.clml.2025.10.007_bib0004","article-title":"High-deductible health plans and out-of-pocket health care costs among younger patients with multiple myeloma","author":"Fiala","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clml.2025.10.007_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JOP.2014.001542","article-title":"Population-based assessment of cancer survivors\u2019 financial burden and quality of life: a prospective cohort study","volume":"11","author":"Zafar","year":"2014","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clml.2025.10.007_bib0006","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","article-title":"Methods for measuring financial toxicity after Cancer diagnosis and treatment: a systematic review and its implications","volume":"30","author":"Witte","year":"2019","journal-title":"Ann Oncol: Official J Eur Soc Med Oncol"},{"key":"10.1016\/j.clml.2025.10.007_bib0007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","article-title":"A systematic review of financial toxicity among Cancer survivors: we can\u2019t pay the co-pay","volume":"10","author":"Gordon","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.clml.2025.10.007_bib0008","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JOP.2013.001322","article-title":"Impact of financial burden of cancer on survivors\u2019 quality of life","volume":"10","author":"Fenn","year":"2014","journal-title":"J Oncol Pract"},{"issue":"suppl","key":"10.1016\/j.clml.2025.10.007_bib0009","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/jco.2015.33.15_suppl.6509","article-title":"Financial insolvency as a risk factor for mortality among patients with cancer","volume":"33","author":"Bansal","year":"2015","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.10.007_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clml.2023.01.008","article-title":"The dynamics of financial toxicity in multiple myeloma","volume":"23","author":"Fiala","year":"2023","journal-title":"Clin Lymph Myelom Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.10.007_bib0011","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1200\/OP.23.00645","article-title":"Mixed-methods study on the responsiveness of the comprehensive score for financial toxicity among people with multiple myeloma","volume":"20","author":"Fiala","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"10.1016\/j.clml.2025.10.007_bib0012","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/OP.24.00016","article-title":"Financial toxicity and willingness-to-pay for cancer treatment among people with multiple myeloma","volume":"20","author":"Fiala","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"10.1016\/j.clml.2025.10.007_bib0013","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2025.10.007_bib0014","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clml.2024.02.013","article-title":"Financial toxicity, time toxicity, and quality of life in multiple myeloma","volume":"24","author":"Banerjee","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.clml.2025.10.007_bib0015","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/ajh.27431","article-title":"At what COST?: a prospective longitudinal cohort assessment of financial toxicity, quality of life, and associated risk factors in patients with plasma cell disorders","volume":"99","author":"Warsame","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2025.151848","article-title":"Different level and difficulties with financial burden in multiple myeloma patients and caregivers: a dyadic qualitative study","author":"Park","year":"2025","journal-title":"Semin Oncol Nurs"},{"issue":"1","key":"10.1016\/j.clml.2025.10.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001570","article-title":"A systematic review of evidence on the links between patient experience and clinical safety and effectiveness","volume":"3","author":"Doyle","year":"2013","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.clml.2025.10.007_bib0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","article-title":"Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States","volume":"18","author":"Hari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.clml.2025.10.007_bib0019","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1002\/cncr.28340","article-title":"Treatment trade-offs in myeloma: a survey of consecutive patients about contemporary maintenance strategies","volume":"119","author":"Burnette","year":"2013","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.clml.2025.10.007_bib0020","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: the COST measure","volume":"120","author":"de Souza","year":"2014","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.10.007_bib0021","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1111\/j.1524-4733.2005.00073.x","article-title":"Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing","volume":"8","author":"Abetz","year":"2005","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.clml.2025.10.007_bib0022","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2022.07.017","article-title":"Comprehensive score for financial toxicity and health-related quality of life in patients with cancer and survivors: a systematic review and meta-analysis","volume":"26","author":"Pangestu","year":"2023","journal-title":"Value Health"},{"issue":"15_suppl","key":"10.1016\/j.clml.2025.10.007_bib0023","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1200\/JCO.2017.35.15_suppl.6615","article-title":"Validation of a financial toxicity (FT) grading system","volume":"35","author":"De Souza","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.007_bib0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.007_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8_Supplement_1","key":"10.1016\/j.clml.2025.10.007_bib0027","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1158\/1538-7445.AM2025-4982","article-title":"Abstract 4982: a randomized controlled trial of financial incentives to improve electronic health record (EHR)-driven recruitment among underrepresented communities","volume":"85","author":"Fiala","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2025.10.007_bib0028","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ahj.2024.06.003","article-title":"Investigating racial and gender disparities in virtual randomized clinical trial enrollment: insights from the BE ACTIVE study","volume":"276","author":"Fortunato","year":"2024","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.clml.2025.10.007_bib0029","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jval.2023.03.011","article-title":"Measuring Financial Toxicity: a Closer Look","volume":"26","author":"LeBlanc","year":"2023","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.clml.2025.10.007_bib0030","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2013-0374","article-title":"Self-reported financial burden and satisfaction with care among patients with cancer","volume":"19","author":"Chino","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2025.10.007_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109604","article-title":"Financial toxicity in cancer patients undergoing radiotherapy in a universal health care system - a prospective multicenter study of 1075 patients","volume":"183","author":"Fabian","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.007_bib0032","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jamcollsurg.2020.10.023","article-title":"Offodile AC 2nd. Correlation Between Financial Toxicity, Quality of Life, and Patient Satisfaction in an Insured Population of Breast Cancer Surgical Patients: a Single-Institution Retrospective Study","volume":"232","author":"Coroneos","year":"2021","journal-title":"J Am Coll Surg"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:18:17Z","timestamp":1770650297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042429"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Financial Toxicity and Satisfaction With Cancer Treatment Among Patients With Multiple Myeloma: An Analysis of the MMRF\u2019s CureCloud Initiative","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}